Management of hepatocellular carcinoma

Minerva Medica

Volumn 100, Issue 1, 2009, Pages 51-68

  Said, A ^a   Wells, J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Carcinoma; Diagnosis Carcinoma; Hepatocellular; Therapy Liver diseases

Indexed keywords

ANTIVIRUS AGENT; PLACEBO; RECOMBINANT INTERFERON; SORAFENIB;

ANTIVIRAL THERAPY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHEMOEMBOLIZATION; CLINICAL TRIAL; DECOMPRESSION SURGERY; DIARRHEA; FATIGUE; HAND FOOT SYNDROME; HEPATITIS B; HUMAN; HYPOPHOSPHATEMIA; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; NONHUMAN; PATIENT SELECTION; PORTAL HYPERTENSION; POSTOPERATIVE COMPLICATION; PROGNOSIS; RADIOFREQUENCY ABLATION; RECURRENT CANCER; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT PLANNING;

EID: 66449110230     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2002;2:37. (Pubitemid 38851284)
2. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127(5 Suppl 1):S27-34. (Pubitemid 39423367)
3. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004;127:1372-1380 (Pubitemid 39457763)
4. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-468 (Pubitemid 38182303)
5. Stravitz RT, Heuman DM, Chand N, Sterling RK, Shiffman ML, Luketic VA et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008;121:119-126
6. Chan AC, Poon RT, Ng KK, Lo CM, Fan ST, Wong J. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening. Ann Surg 2008;247:666-673
7. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-338 (Pubitemid 29488775)
8. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917
9. Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996;111:1018-1022
10. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-1440
11. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008;134:1908-16.
12. Ng KK, Vauthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J et al. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 2005;12:364-373
13. Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, Curley SA et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005;140:450-7; discussion 457-458
14. Esnaola NF, Mirza N, Lauwers GY, Ikai I, Regimbeau JM, Belghiti J et al. Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. Ann Surg 2003;238:711-719
15. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236 (Pubitemid 43112690)
16. Ozawa K, Takayasu T, Kumada K, Yamaoka Y, Tanaka K, Kobayashi N et al. Experience with 225 hepatic resections for hepatocellular carcinoma over a 4-year period. Am J Surg 1991;161:677-682
17. Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal. Ann Surg 2000;231:544-551 (Pubitemid 30185862)
18. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Yamamoto J, Shimada K et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 1998;28:1241-1246
19. Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 2003;238:703-710 (Pubitemid 38182262)
20. Ikegami T, Shimada M, Imura S, Yoshizumi T, Arakawa Y, Tokunaga T et al. The timing of liver transplantation after primary hepatectomy for hepatocellular carcinoma: a special reference to recurrence pattern and Milan criteria. Transplantation 2008;86:641-646
21. Facciuto ME, Koneru B, Rocca JP, Wolf DC, Kim-Schluger L, Visintainer P et al. Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation. Ann Surg Oncol 2008;15:1383-91.
22. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.
23. Bellavance EC, Lumpkins KM, Mentha G, Marques HP, Capussotti L, Pulitano C et al. Surgical management of early-stage hepatocellular carcinoma: resection or transplantation? J Gastrointest Surg 2008;12:1699-1708
24. Mazzafeno V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543-1554
25. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699
26. Llovet JM, Bruix J, Fuster J, Castells A, Garcia-Valdecasas JC, Grande L et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 1998;27:1572-1577
27. Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001;33:1080-1086
28. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-151
29. Olthoff KM, Millis JM, Rosove MH, Goldstein LI, Ramming KP, Busuttil RW. Is liver transplantation justified for the treatment of hepatic malignancies? Arch Surg 1990;125:1261-6; discussion 1266-1268
30. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991;110:726-34; discussion 734-735
31. Iwatsuki S, Starzl TE, Sheahan DG, Yokoyama I, Demetris AJ, Todo S et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991;214:221-8; discussion 228-229
32. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008;143:182-8; discussion 188.
33. Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 2004;127(5 Suppl 1):S261-7. (Pubitemid 39423395)
34. Molmenti EP, Klintmalm GB. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl 2002;8:736-748
35. Lauwers GY, Terris B, Balis UJ, Batts KP, Regimbeau JM, Chang Y et al. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol 2002;26:25-34.
36. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005;11:1086-1092
37. Tamura S, Kato T, Berho M, Misiakos EP, O'Brien C, Reddy KR et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001;136:25-30: discussion 31.
38. Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, Zanus G et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004;239:150-159
39. Ioannou GN, Perkins JD, Carithers RL, Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008;134:1342-1351
40. Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008;248:857-862
41. Vivarelli M, Cucchetti A, Piscaglia F, La Barba G, Bolondi L, Cavallari A et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005;11:497-503.
42. Wang Z, Fan J, Zhou J, Wu ZQ, Qiu SJ, Yu Y et al. [Inhibition of growth and metastasis of hepatocellular carcinoma by rapamycin: experiment with mice]. Zhonghua Yi Xue Za Zhi 2006;86:1666-1670
43. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008;14:633-638
44. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007;7:2587-2596 (Pubitemid 47561609)
45. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002;8:765-774
46. Onaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2007;13:391-399 (Pubitemid 46444468)
47. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007;246:502-9; discussion 509-511
48. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, Meyer C, Gugenheim J, Durand F, et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 2006;12:1761-1769
49. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-403.
50. Sutcliffe R, Maguire D, Portmann B, Rela M, Heaton N. Selection of patients with hepatocellular carcinoma for liver transplantation. Br J Surg 2006;93:11-18 (Pubitemid 43117299)
51. Inagawa S, Itabashi M, Adachi S, Kawamoto T, Hori M, Shimazaki J et al. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 2002;8:450-456
52. Ito Y, Matsuura N, Sakon M, Takeda T, Umeshita K, Nagano H et al. Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br J Cancer 1999;81:747-751
53. Kobayashi T, Kubota K, Takayama T, Makuuchi M. Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. Am J Surg 2001;181:284-288 (Pubitemid 32480232)
54. Nanashima A, Yano H, Yamaguchi H, Tanaka K, Shibasaki S, Sumida Y et al. Immunohistochemical analysis of tumor biological factors in hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection. J Gastroenterol 2004;39:148-154
55. Qin LX. Chromosomal aberrations related to metastasis of human solid tumors. World J Gastroenterol 2002;8:769-776
56. Qin LX, Tang ZY, Ma ZC, Wu ZQ, Zhou XD, Ye QH et al. P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol 2002;8:459-63.
57. Yao FY, Kerlan RK, Jr., Hirose R, Davern TJ, 3rd, Bass NM, Feng S et al. Excellent outcome following downstaging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008;48:819-827
58. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003;9:557-563
59. Yao FY, Hirose R, LaBerge JM, Davern TJ, 3rd, Bass NM, Kerlan RK, Jr. et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005;11:1505-1514
60. Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007;13:272-279.
61. Schwarz RE, Smith DD. Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. Am J Surg 2008;195:829-836
62. Fuke H, Sugimoto K, Shiraki K, Tanaka J, Beppu T, Yoneda K et al. Predictive factors for distant recurrence of HCV-related hepatocellular carcinoma after radiofrequency ablation combined with chemoembolization. Aliment Pharmacol Ther 2008;27:1253-1260
63. Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004;240:900-909
64. Brillet PY, Paradis V, Brancatelli G, Rangheard AS, Consigny Y, Plessier A et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma before liver transplantation: a prospective study with histopathologic comparison. AJR Am J Roentgenol 2006;186(5 Suppl):S296-305.
65. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005;54:1151-1156 (Pubitemid 41025911)
66. Hasegawa S, Yamasaki N, Hiwaki T, Sako K, Komorizono Y, Baba Y et al. Factors that predict intrahepatic recurrence of hepatocellular carcinoma in 81 patients initially treated by percutaneous ethanol injection. Cancer 1999;86:1682-1690
67. Sala M, Llovet JM, Vilana R, Bianchi L, Sole M, Ayuso C et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40:1352-1360
68. Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995;197:101-108
69. Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. Jama 2008;299:1669-1677
70. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171
71. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739
72. Salmi A, Turrini R, Lanzani G, Viviani G, Zappella A, Savio A et al. Long-term effectiveness of radiofrequency ablation for hepatocellular carcinoma of 3-5 cm or less. Hepatogastroenterology 2008;55:191-196
73. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008;47:82-89
74. Murakami T, Ishimaru H, Sakamoto I, Uetani M, Matsuoka Y, Daikoku M et al. Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence. Cardiovasc Intervent Radiol 2007;30:696-704.
75. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321-328
76. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6-25.
77. Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005;103:1201-1209
78. Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005;234:961-967
79. Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J, Tung H et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg 2008;207:20-29
80. Nouso K, Matsumoto E, Kobayashi Y, Nakamura S, Tanaka H, Osawa T et al. Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies. J Gastroenterol Hepatol 2008;23:453-458
81. Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M et al. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol 2008;49:589-594
82. Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005;41:1130-1137
83. Bharat A, Brown DB, Crippin JS, Gould JE, Lowell JA, Shenoy S et al. Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg 2006;203:411-420
84. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005;11:767-775
85. Yao FY, Bass NM, Nikolai B, Merriman R, Davern TJ, Kerlan R et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003;9:684-692
86. Porrett PM, Peterman H, Rosen M, Sonnad S, Soulen M, Markmann JF et al. Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl 2006;12:665-673
87. Otto G, Herber S, Heise M, Lohse AW, Monch C, Bittinger F et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006;12:1260-1267
88. Otto G, Heise M, Moench C, Herber S, Bittinger F, Schuchmann M et al. Transarterial chemoembolization before liver transplantation in 60 patients with hepatocellular carcinoma. Transplant Proc 2007;39:537-539
89. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995;31:1237-1248
90. Minsky BD, Leibel SA. The treatment of hepatic metastases from colorectal cancer with radiation therapy alone or combined with chemotherapy or misonidazole. Cancer Treat Rev 1989;16:213-219 (Pubitemid 20205942)
91. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008;26:657-664
92. Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004;60:1552-1563
93. Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S194-205.
94. Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud M et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004;15:335-345
95. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109
96. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390
97. Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 2008;134:379.
98. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993;17:389-394
99. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-58
100. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005;54(RR-16):1-31.
101. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006;55(RR-16):1-33; quiz CE1-4.
102. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: A historical overview. Vaccine 2008;26:6266-6273
103. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 2006;295:65-73.
104. Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006;11:985-994
105. La Vecchia C. Coffee, liver enzymes, cirrhosis and liver cancer. J Hepatol 2005;42:444-446 (Pubitemid 40342918)
106. Bravi F, Bosetti C, Tavani A, Bagnardi V, Gallus S, Negri E et al. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology 2007;46:430-435
107. Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 2007;132: 1740-1745 (Pubitemid 46677953)